This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Antibiotic Resistance 2013: The Antibiotics Development Pipeline And Strategies To Combat Antibiotic Resistance

Table 4.5 Antibiotics in preclinical development (Source: Biopharm Reports, 2013)

Figures

Figure 2.1 Escherichia coli: trends of resistance to aminopenicillin by country, 2007–2010

Figure 2.2 Escherichia coli: trends of resistance to third-generation cephalosporins by country, 2007–2010

Figure 2.3 Escherichia coli: trends of resistance to fluoroquinolones by country, 2007–2010

Figure 2.4 Escherichia coli: trends of resistance to aminoglycosides by country, 2007–2010

Figure 2.5 Escherichia coli: trends of combined resistance (resistant to fluoroquinolones,

third-generation cephalosporins and aminoglycosides) by country, 2007–2010

Figure 2.6 Streptococcus pneumoniae: trends of non-susceptibility to penicillin by country, 2007–2010

Figure 2.7 Streptococcus pneumoniae: trends of non-susceptibility to macrolides by country, 2007–2010

Figure 2.8 Staphylococcus aureus: trends of resistance to meticillin (MRSA) by country, 2007–2010

Figure 2.9 Enterococcus faecalis: trends of high-level resistance to aminoglycosides by country, 2007–2010

Figure 2.10 Enterococcus faecium: trends of resistance to vancomycin by country 2007–2010

Figure 2.11 Klebsiella pneumoniae: trends of resistance to third-generation cephalosporins by country, 2007–2010

Figure 2.12 Klebsiella pneumoniae: trends of resistance to fluoroquinolones by country, 2007–2010

Figure 2.13 Klebsiella pneumoniae: trends of resistance to aminoglycosides by country, 2007–2010

Figure 2.14 Klebsiella pneumoniae: trends of resistance to carbapenems by country, 2007–2010

Figure 2.15 Klebsiella pneumoniae: trends of combined resistance (third-generation cephalosporins, fluoroquinolones and aminoglycosides) by country, 2007–2010

Figure 2.16 Pseudomonas aeruginosa: trends of resistance to piperacillin±tazobactam by country, 2007–2010

Figure 2.17 Pseudomonas aeruginosa: trends of resistance to ceftazidime by country, 2007–2010

Figure 2.18 Pseudomonas aeruginosa: trends of resistance to fluoroquinolones by country, 2007–2010

Figure 2.19 Pseudomonas aeruginosa: trends of resistance to aminoglycosides by country, 2007–2010

Figure 2.20 Pseudomonas aeruginosa: trends of resistance to carbapenems by country, 2007–2010

Figure 2.21 Pseudomonas aeruginosa: trends of combined resistance (R to three or more antibiotic classes among piperacillin±tazobactam, ceftazidime, fluoroquinolones, aminoglycosides and carbapenems) by country, 2007–2010

Figure 2.22 Antibiotic resistance of Staphylococcus, Streptococcus, Escherichia coli and Enterococcus in the US, Egypt and Tunisia 2.1

Figure 3.1 Current fully approved/marketed antibiotics for the treatment of bacterial and fungal infections (Source: Biopharm Reports, 2013).

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,435.06 +26.52 0.16%
S&P 500 1,868.25 +3.40 0.18%
NASDAQ 4,104.5170 +9.0010 0.22%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs